Community Bank N.A. Grows Position in Pfizer Inc. (NYSE:PFE)

Community Bank N.A. raised its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 15.1% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 89,748 shares of the biopharmaceutical company's stock after purchasing an additional 11,796 shares during the period. Community Bank N.A.'s holdings in Pfizer were worth $2,274,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in PFE. Rialto Wealth Management LLC purchased a new stake in shares of Pfizer in the fourth quarter worth $26,000. Clarity Asset Management Inc. purchased a new position in shares of Pfizer in the fourth quarter valued at about $27,000. Gould Capital LLC boosted its stake in shares of Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 493 shares during the period. Kohmann Bosshard Financial Services LLC purchased a new stake in shares of Pfizer during the fourth quarter worth about $28,000. Finally, Bernard Wealth Management Corp. purchased a new position in Pfizer in the 4th quarter worth approximately $30,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Trading Down 1.6%

PFE stock opened at $24.00 on Wednesday. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The stock has a market capitalization of $136.47 billion, a price-to-earnings ratio of 17.39, a price-to-earnings-growth ratio of 0.89 and a beta of 0.57. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. The firm's fifty day simple moving average is $23.14 and its two-hundred day simple moving average is $24.93.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The firm's revenue for the quarter was down 7.8% compared to the same quarter last year. During the same period in the previous year, the company earned $0.82 EPS. As a group, analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, June 13th. Stockholders of record on Friday, May 9th were issued a $0.43 dividend. The ex-dividend date was Friday, May 9th. This represents a $1.72 annualized dividend and a dividend yield of 7.17%. Pfizer's payout ratio is 124.64%.

Analyst Upgrades and Downgrades

PFE has been the topic of several research analyst reports. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. UBS Group boosted their price target on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Finally, Cantor Fitzgerald assumed coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price target on the stock. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $29.17.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.